Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2382-2392

  Chiappalupi, Sara ^a,b   Riuzzi, Francesca ^a,b   Fulle, Stefania ^b,c   Donato, Rosario ^a,b   Sorci, Guglielmo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Interuniversity Institute of Myology (IIM)   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; EPHRIN A1; EPHRIN RECEPTOR A3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYOGENIN; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR PAX7; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CD56 ANTIGEN; EPHA3 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LEUPEPTIN; NCAM1 PROTEIN, HUMAN; PAX7 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ECTOPIC EXPRESSION; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RHABDOMYOSARCOMA CELL LINE; TRANSCRIPTION REGULATION; TUMOR INVASION; UPREGULATION; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; NUDE MOUSE; PATHOLOGY; RHABDOMYOSARCOMA, EMBRYONAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD56; CELL LINE, TUMOR; CELL MOVEMENT; EPHRIN-A1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUPEPTINS; MICE; MICE, MUTANT STRAINS; MICE, NUDE; MYOBLASTS; MYOGENIN; PAX7 TRANSCRIPTION FACTOR; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, IMMUNOLOGIC; RHABDOMYOSARCOMA, EMBRYONAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918834536     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu176     Document Type: Article

References (49)

1. Pappo, A.S. (1996) Rhabdomyosarcoma and other soft tissue sarcomas in children. Curr. Opin. Oncol., 8, 311-316.
2. Parham, D.M. et al. (2006) Rhabdomyosarcomas in adults and children: an update. Arch. Pathol. Lab. Med., 130, 1454-1465.
3. Saab, R. et al. (2011) Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr. Top. Dev. Biol., 94, 197-234.
4. Tiffin, N. et al. (2003) PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer, 89, 327-332.
5. Rubin, B.P. et al. (2011) Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell, 19, 177-191.
6. Fritz, G. (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem. Sci., 36, 625-632.
7. Sorci, G. et al. (2013) RAGE in tissue homeostasis, repair and regeneration. Biochim. Biophys. Acta, 1833, 101-109.
8. Sorci, G. et al. (2004) Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol. Cell. Biol., 24, 4880-4894.
9. Riuzzi, F. et al. (2012) HMGB1-RAGE regulates muscle satellite cell homeostasis through p38-MAPK-and myogenin-dependent repression of Pax7 transcription. J. Cell Sci., 125(Pt 6), 1440-1454.
10. Riuzzi, F. et al. (2006) The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo. J. Biol. Chem., 281, 8242-8253.
11. Riuzzi, F. et al. (2007) RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am. J. Pathol., 171, 947-961.
12. Blake, J. et al. (2003) Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma? Histol. Histopathol., 18, 529-539.
13. Olguin, H.C. et al. (2007) Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. J. Cell Biol., 177, 769-779.
14. Riuzzi, F. et al. (2014) RAGE signaling deficiency in rhabdomyosarcoma cells causes upregulation of PAX7 and uncontrolled proliferation. J. Cell Sci., 127(Pt 8), 1699-1711.
15. Purdy, A.K. et al. (2009) Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol. Ther., 8, 2211-2220.
16. Daniel, L. et al. (2001) A nude mice model of human rhabdomyosarcoma lung metastases for evaluating the role of polysialic acids in the metastatic process. Oncogene, 20, 997-1004.
17. Beccafico, S. et al. (2011) Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. Age (Dordr)., 33, 523-541.
18. Olguin, H.C. et al. (2004) Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev. Biol., 275, 375-388.
19. Taulli, R. et al. (2006) Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res., 66, 4742-4749.
20. Corso, S. et al. (2005) Cancer therapy: can the challenge be MET? Trends Mol. Med., 11, 284-292.
21. Campbell, T.N. et al. (2008) The Eph receptor/ephrin system: an emerging player in the invasion game. Curr. Issues Mol. Biol., 10, 61-66.
22. Fernández-Briera, A. et al. (2010) Effect of human colorectal carcinogenesis on the neural cell adhesion molecule expression and polysialylation. Oncology, 78, 196-204.
23. Huang, daW. et al. (2009) Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Prot., 4, 44-57.
24. Sebire, N.J. et al. (2003) Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J. Clin. Pathol., 56, 412-416.
25. Reimann, J. et al. (2004) Pax7 distribution in human skeletal muscle biopsies and myogenic tissue cultures. Cell Tissue Res., 315, 233-242.
26. Zammit, P.S. et al. (2006) Pax7 and myogenic progression in skeletal muscle satellite cells. J. Cell Sci., 119(Pt 9), 1824-1832.
27. Jostes, B. et al. (1990) The murine paired box gene, Pax7, is expressed specifically during the development of the nervous and muscular system. Mech. Dev., 33, 27-37.
28. Tremblay, P. et al. (1998) A crucial role for Pax3 in the development of the hypaxial musculature and the long-range migration of muscle precursors. Dev. Biol., 203, 49-61.
29. Henderson, D.J. et al. (1999) Rib truncations and fusions in the Sp2H mouse reveal a role for Pax3 in specification of the ventro-lateral and posterior parts of the somite. Dev. Biol., 209, 143-158.
30. Swartz, M.E. et al. (2001) EphA4/ephrin-A5 interactions in muscle precursor cell migration in the avian forelimb. Development, 128, 4669-4680.
31. Pasquale, E.B. (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer, 10, 165-180.
32. Clifford, N. et al. (2008) The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J. Cell. Biochem., 105, 1250-1259.
33. Iida, H. et al. (2005) Ephrin-A1 expression contributes to the malignant characteristics of (alpha)-fetoprotein producing hepatocellular carcinoma. Gut, 54, 843-851.
34. Alford, S.C. et al. (2007) Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp. Cell Res., 313, 4170-4179.
35. Cavallaro, U. et al. (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat. Cell Biol., 3, 650-657.
36. Mühlenhoff, M. et al. (1998) Polysialic acid: three-dimensional structure, biosynthesis and function. Curr. Opin. Struct. Biol., 8, 558-564.
37. Chalepakis, G. et al. (1994) Pax-3 contains domains for transcription activation and transcription inhibition. Proc. Natl. Acad. Sci. U. S. A., 91, 12745-12749.
38. Mayanil, C.S. et al. (2001) Microarray analysis detects novel Pax3 downstream target genes. J. Biol. Chem., 276, 49299-49309.
39. Sessa, L. et al. (2014) The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS One, 9, e86903.
40. Langley, B. et al. (2004) Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene, 23, 524-534.
41. Pavlath, G.K. (2002) Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis. J. Neuroimmunol., 125, 42-50.
42. Cavacini, L.A. et al. (1992) Effect of immunosuppressive therapy on cytolytic activity of immunodeficient mice: implications for xenogeneic transplantation. Cell. Immunol., 144, 296-310.
43. Keller, C. et al. (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev., 18, 2614-2626.
44. Hettmer, S. et al. (2010) Muscling in: uncovering the origins of rhabdomyosarcoma. Nat. Med., 16, 171-173.
45. Sparvero, L.J. et al. (2009) RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med., 7, 17.
46. Bartling, B. et al. (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis, 26, 293-301.
47. Landesberg, R. et al. (2008) The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 105, 617-624.
48. Tateno, T. et al. (2009) Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma. Ann. Surg. Oncol., 16, 440-446.
49. Nanni, P. et al. (2009) Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol. Cancer Ther., 8, 754-761.